CARsgen Therapeutics and Huadong Medicine (Hangzhou) will collaborate on the commercialisation of CARsgen’s BCMA CAR-T product CT053 in mainland China. CT053 (zevorcabtagene autoleucel, Zevor-cel) is CARsgen’s lead drug candidate and an autologous CAR T-cell product treating relapsed/refractory multiple myeloma (R/R MM). Dr Zonghai Li, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer […]
Menu ≡ ╳ 
